Immunomodulatory effects of MSCs in attenuating GVHD are mediated by secretion of cytokines (IL-6, TGF-β), soluble receptors (PDL-1, PDL-2) and effector molecules (nitric oxide, PGE2). Here, IL6 is linked to graft versus host disease.